Type 2 Diabetes Mellitus Clinical Trial
Official title:
Iron Reduction by Phlebotomy for the Prevention and Treatment of Type 2 Diabetes
High tissue iron is a risk factor for diabetes even within the broad normal range of normal human values. In order to demonstrate the benefits of reducing iron on glucose homeostasis and to better define the parameters for larger clinical trials, the investigators will subject individuals with prediabetes (impaired glucose tolerance, IGT) or early type 2 diabetes to phlebotomy in order to reduce serum ferritin concentrations and determine the effect on glucose homeostasis as revealed by oral and frequently sampled intravenous glucose tolerance testing.
Male and female subjects aged 35-65 will be recruited from the clinic populations at the
Medical Centers of the Universities of Colorado, New Mexico, or Utah who have prediabetes,
or diabetes relatively well-controlled (Hemoglobin A1c [HbA1c] ≤ 8.0%) with a single oral
agent. Diabetes/prediabetes status is verified by oral glucose tolerance testing (OGTT)
using criteria of the American Diabetes Association. Serum ferritin will be determined, and
subjects chosen with values in the upper 50% of the normal range, 110-400 ng/mL for males,
or 80-240 for females. Exclusion criteria include: hereditary hemochromatosis; cancer
(except cases currently with no evidence of disease); serum creatinine >1.5; anemia (Hgb <
lower limit of normal); chronic inflammatory conditions (rheumatologic conditions such as
rheumatoid arthritis or giant cell arteritis, or chronic infections such as hepatitis B or
C) that could affect ferritin; erythrocyte sedimentation rate or C-reactive protein>1.5
times the upper limit of normal (UNL); serum transaminases 2 x UNL; hemophilia, warfarin
therapy, or history of GI bleeding; and current glucocorticoid therapy.
After determination of eligibility, subjects are randomized in a 2:1 ratio for treatment and
controls arms. In the fasted state, blood is drawn for determination of adiponectin and
lipids (HDL, direct LDL, triglycerides). Subjects have the option of participating in a
frequently sampled intravenous glucose tolerance test (FSIVGTT). All subjects receive
counseling to follow a healthy diet and regular exercise. Phlebotomy occurs at the rate of
500 ml (one Unit) of blood per month over the period of 3-6 months. At two-month intervals,
serum ferritin and complete blood counts are determined. When serum ferritin reaches the
lowest quartile of normal (<50 ng/mL for females and <70 ng/mL for males, but no sooner than
3 months or later than 6 months after beginning phlebotomy, metabolic status will be
reassessed by fasting lipids, adiponectin, OGTT, and optionally, FSIVGTT. Controls are
recalled for repeat testing 6-8 months after enrollment.
120 min OGTT and FSIVGTT are performed on separate days after an overnight fast. FSIVGTT
data are analyzed using MINMOD Millennium software. Areas under the glucose curve
(AUCglucose) are calculated using the trapezoidal method.
;
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02771093 -
An Exploratory Study of the Effects of Trelagliptin and Alogliptin on Glucose Variability in Patients With Type 2 Diabetes Mellitus
|
Phase 4 | |
Completed |
NCT02545842 -
Assessment Study of Three Different Fasting Plasma Glucose Targets in Chinese Patients With Type 2 Diabetes Mellitus (BEYOND III/FPG GOAL)
|
Phase 4 | |
Recruiting |
NCT03436212 -
Real-Life Home Glucose Monitoring Over 14 Days in T2D Patients With Intensified Therapy Using Insulin Pump.
|
N/A | |
Completed |
NCT03244800 -
A Study to Investigate Different Doses of 0382 in Overweight and Obese Subjects With Type 2 Diabetes Mellitus.
|
Phase 2 | |
Completed |
NCT03960424 -
Diabetes Management Program for Hispanic/Latino
|
N/A | |
Withdrawn |
NCT02769091 -
A Study in Adult Patients With Nonalcoholic Steatohepatitis Who Also Have Type 2 Diabetes
|
Phase 2 | |
Recruiting |
NCT06065540 -
A Research Study to See How Well CagriSema Compared to Semaglutide, Cagrilintide and Placebo Lowers Blood Sugar and Body Weight in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor
|
Phase 3 | |
Recruiting |
NCT05008276 -
Puberty, Diabetes, and the Kidneys, When Eustress Becomes Distress (PANTHER Study)
|
||
Completed |
NCT04091373 -
A Study Investigating the Pharmacokinetics of a Single Dose Administration of Cotadutide
|
Phase 1 | |
Completed |
NCT03296800 -
Study to Evaluate Effects of Probenecid, Rifampin and Verapamil on Bexagliflozin in Healthy Subjects
|
Phase 1 | |
Recruiting |
NCT06212778 -
Relationship Between Nutritional Status, Hand Grip Strength, and Fatigue in Hospitalized Older Adults With Type 2 Diabetes Mellitus.
|
||
Completed |
NCT05979519 -
Fresh Carts for Mom's to Improve Food Security and Glucose Management
|
N/A | |
Recruiting |
NCT05579314 -
XW014 in Healthy Subjects and Patients With Type 2 Diabetes Mellitus (T2DM)
|
Phase 1 | |
Completed |
NCT03859934 -
Metabolic Effects of Melatonin Treatment
|
Phase 1 | |
Terminated |
NCT03684642 -
Efficacy and Safety of Efpeglenatide Versus Dulaglutide in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin
|
Phase 3 | |
Completed |
NCT03248401 -
Effect of Cilostazol on Carotid Atherosclerosis Estimated by 3D Ultrasound in Patients With Type 2 Diabetes
|
Phase 4 | |
Completed |
NCT03644134 -
A Personalized Intervention to Manage Physiological Stress and Improve Sleep Patterns
|
N/A | |
Completed |
NCT05295160 -
Fasting-Associated Immune-metabolic Remission of Diabetes
|
N/A | |
Completed |
NCT02836873 -
Safety and Efficacy of Bexagliflozin in Type 2 Diabetes Mellitus Patients With Moderate Renal Impairment
|
Phase 3 | |
Completed |
NCT02252224 -
Forxiga (Dapagliflozin) Regulatory Postmarketing Surveillance
|